Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Resmed (RMD – Research Report) and Clinigence Holdings (NUTX – Research Report).
Insulet (PODD)
In a report released today, Matthew O’Brien from Piper Sandler reiterated a Buy rating on Insulet, with a price target of $250.00. The company’s shares closed last Wednesday at $201.19.
According to TipRanks.com, O’Brien is a 5-star analyst with an average return of
Insulet has an analyst consensus of Strong Buy, with a price target consensus of $224.21.
See Insiders’ Hot Stocks on TipRanks >>
Resmed (RMD)
RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Resmed today and set a price target of $182.00. The company’s shares closed last Wednesday at $171.78.
According to TipRanks.com, Wong-Pan is a 2-star analyst with an average return of
Resmed has an analyst consensus of Strong Buy, with a price target consensus of $167.08.
Clinigence Holdings (NUTX)
In a report released today, Bill Sutherland from Benchmark Co. initiated coverage with a Buy rating on Clinigence Holdings and a price target of $1.00. The company’s shares closed last Wednesday at $0.14, close to its 52-week low of $0.14.
According to TipRanks.com, Sutherland is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Clinigence Holdings with a $1.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PODD:
- Insulet recalls Omnipod 5 Android app over software error, FDA says
- Salesforce upgraded, Chipotle downgraded: Wall Street’s top analyst calls
- Insulet upgraded to Outperform from Neutral at Baird
- These 2 MedTech Stocks Look Too Cheap to Ignore, Says Morgan Stanley
- GM upgraded, Lululemon downgraded: Wall Street’s top analyst calls
